Having identified the JAK/STAT pathway as an actionable therapeutic target in TEN using spatial proteomics, and given our extensive preclinical evidence, we treated seven patients with TEN or SJS–TEN overlap syndrome, including three who were previously unresponsive to high-dose systemic corticosteroids. This evidence concerns the gene SOAT1 and Schwartz-Jampel syndrome.